Avalo Therapeutics (AVTX) director awarded 29,500 options at $13.96 strike

Q: What are the key terms of Michael Heffernan’s Avalo Therapeutics stock option grant?

The grant covers 29,500 stock options with an exercise price of $13.96 per share . The options relate to Avalo Therapeutics common stock and are scheduled to expire on June 2, 2036 , if not previously exercised or forfeited.

Q: When do Michael Heffernan’s Avalo Therapeutics stock options vest?

The options vest 100% on the first anniversary of the grant date. Vesting is conditioned on Heffernan’s continued service as a director through that vesting date, according to the Form 4 footnote.

Q: How many Avalo Therapeutics options does Michael Heffernan hold after this transaction?

Following this grant, Michael Heffernan holds 29,500 stock options directly. The Form 4 shows this as his total derivative holdings after the transaction, reflecting the full amount of the new award.

Q: Is Michael Heffernan’s Avalo Therapeutics Form 4 a stock buy or sell in the market?

No, this Form 4 reports a grant of stock options , not an open-market buy or sell. The transaction is coded as a grant or award, providing the right to buy shares later at $13.96 per share .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. director Michael Thomas Heffernan received a grant of stock options as compensation. He was awarded 29,500 stock options, each giving the right to buy common stock at an exercise price of $13.96 per share. The options vest 100% on the first anniversary of the grant date, provided he continues to serve as a director on that vesting date. After this grant, he holds 29,500 stock options directly, and the options are scheduled to expire on June 2, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Heffernan Michael Thomas

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	29,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 29,500 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 29,500 options Exercise price: $13.96 per share Expiration date: June 2, 2036 +2 more

5 metrics

Stock options granted 29,500 options Grant to director Michael Thomas Heffernan

Exercise price $13.96 per share Strike price for the 29,500 options

Expiration date June 2, 2036 Options’ scheduled expiration

Post-grant option holdings 29,500 options Total derivative holdings after transaction

Vesting schedule 100% after 1 year Vests on first anniversary, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Common Stock, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "13.9600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vests 100% on the first anniversary financial

"The stock option vests 100% on the first anniversary of the date of grant"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/04/2026 - 04:10 PM Accepted by SEC EDGAR 06/04/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heffernan Michael Thomas

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.96	06/02/2026		A		29,500		⁽¹⁾	06/02/2036	Common Stock	29,500	$0	29,500	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Avalo Therapeutics (AVTX) director Michael Heffernan report on this Form 4?

Michael Thomas Heffernan reported receiving a grant of stock options for 29,500 shares of Avalo Therapeutics common stock. These options are a form of equity compensation, not an open-market stock purchase or sale.

What are the key terms of Michael Heffernan’s Avalo Therapeutics stock option grant?

The grant covers 29,500 stock options with an exercise price of $13.96 per share. The options relate to Avalo Therapeutics common stock and are scheduled to expire on June 2, 2036, if not previously exercised or forfeited.

When do Michael Heffernan’s Avalo Therapeutics stock options vest?

The options vest 100% on the first anniversary of the grant date. Vesting is conditioned on Heffernan’s continued service as a director through that vesting date, according to the Form 4 footnote.

How many Avalo Therapeutics options does Michael Heffernan hold after this transaction?

Following this grant, Michael Heffernan holds 29,500 stock options directly. The Form 4 shows this as his total derivative holdings after the transaction, reflecting the full amount of the new award.

Is Michael Heffernan’s Avalo Therapeutics Form 4 a stock buy or sell in the market?

No, this Form 4 reports a grant of stock options, not an open-market buy or sell. The transaction is coded as a grant or award, providing the right to buy shares later at $13.96 per share.